Last reviewed · How we verify
NCT06157671
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
trial in Pancreatic Adenocarcinoma in 1,000 participants. Enrolling by invitation.
1 January 2030
Quick facts
| Lead sponsor | Adenocyte, LLC |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 31 January 2024 |
| Primary completion | 1 January 2030 |
| Estimated completion | 1 June 2030 |
| Sites | 1 location across United States |
Conditions studied
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
- Pancreatic Intraepithelial Neoplasia — all drugs for Pancreatic Intraepithelial Neoplasia →
Sponsor
Adenocyte, LLC
Who can join
Adults 18 to 90, any sex, with Pancreatic Adenocarcinoma or Pancreatic Intraepithelial Neoplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural network-based computer-assisted system may be utilized to enhance the analysis. Patients enrolled are being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06157671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
- NCT06896188 — 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLE · Phase 1 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Adenocyte, LLC trials
Trials by the same sponsor.
- NCT06276764 — The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) · enrolling by invitation
- NCT06276803 — The LINFU® U.S. Registry for the in the General Population Without Risk Factors · not yet recruiting
- NCT06276738 — The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease · not yet recruiting
- NCT04793633 — Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer · enrolling by invitation
- NCT05161013 — A Proof-of-Concept Study Evaluating LINFU™ · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06157671 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Adenocyte, LLC
- Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06157671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing